Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment

Eur J Hum Genet. 2010 May;18(5):614-7. doi: 10.1038/ejhg.2009.212. Epub 2009 Nov 25.


Neurofibromatosis type 1 is one of the most common neurocutaneous autosomal dominant disorders. It is caused by mutations in the neurofibromatosis type 1 (NF1) gene and approximately 30-40% of them affect the correct splicing of NF1 pre-mRNA. In this report, we evaluate the effect of five different drugs, previously found to modify splicing in several genetic disorders, on the splicing of mutated NF1 alleles. For this purpose, cell lines derived from patients bearing 19 different NF1-splicing defects were used. Our results showed that kinetin partially corrects the splicing defect in four of the studied mutations (c.910C>T, c.3113G>A, c.6724C>T and c.6791dupA). Our study is a valuable contribution to the field because it identifies new exon-skipping events that can be reversed by kinetin treatment and provides new information about kinetin splicing modulation. However, owing to the nature of mutations in our patients, kinetin treatment could not be used as a therapeutic agent in these cases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing / drug effects*
  • Alternative Splicing / genetics*
  • Cell Line
  • Humans
  • Kinetin / pharmacology*
  • Neurofibromin 1 / genetics*
  • Neurofibromin 1 / metabolism
  • RNA Precursors / genetics*
  • RNA Precursors / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism


  • Neurofibromin 1
  • RNA Precursors
  • RNA, Messenger
  • Kinetin